A Lancet commentary examines whether the rVSVΔG-ZEBOV-GP vaccine's induced seroreactivity offers real protection against Bundibugyo virus, which has caused 5,815 confirmed cases and 2,788 deaths in the Democratic Republic of the Congo as of August 27, 2026.
Ebola Vaccine's Cross-Protection Against Bundibugyo Virus Questioned as Outbreak Grows
A Lancet commentary examines whether the rVSVΔG-ZEBOV-GP vaccine's induced seroreactivity offers real protection against Bundibugyo virus, which has caused 5,815 confirmed cases and 2,788 deaths in the Democratic Republic of the Congo as of August 27, 2026.
![[Comment] rVSVΔG-ZEBOV-GP vaccine-induced seroreactivity to Bundibugyo virus: a cross-protection dilemma](https://nbg1.your-objectstorage.com/ckln/image-assets/a49ec87aba3188b3428e154ded33f620c60b672120c475de7731a56cecbbe36c.jpg)
Bundibugyo ebolavirus · Wikimedia — licence per file · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.